Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika to Showcase Joint Preservation and Restoration Portfolio at the Annual Scientific Meeting of the International Society for Hip Arthroscopy
BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 16, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid ("HA") technology platform , today announced plans to showcase its
View HTML
Toggle Summary Anika Appoints Mira Leiwant as Vice President of Regulatory Affairs, Quality, and Clinical Affairs
Industry veteran brings extensive experience leading global regulatory, quality, and clinical affairs teams BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 14, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated company, focused on developing regenerative therapies leveraging its
View HTML
Toggle Summary Anika to Issue Third-quarter 2019 Financial Results and Business Highlights on Thursday, October 24
  BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 10, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2019 financial results after the close of the market on Thursday, October 24, 2019 and hold its investor conference call on the same day,
View HTML
Toggle Summary Anika to Showcase Joint Preservation and Restoration Portfolio at the 2019 World Congress of the International Cartilage Regeneration and Joint Preservation Society
  BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 4, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated regenerative therapies company leveraging its proprietary hyaluronic acid ("HA") technology platform , today announced plans to showcase its osteoarthritis pain management and joint
View HTML
Toggle Summary Anika Commences U.S. Commercial Launch of TACTOSET Bone Repair Therapy Under Its New U.S. Hybrid Commercial Model
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 18, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company leveraging its proprietary hyaluronic acid ("HA") technology platform to provide therapies across the Joint Preservation and Restoration continuum of care,
View HTML
Toggle Summary Anika Therapeutics to Host Analyst and Investor Day on September 18, 2019
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 4, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that it will host an Analyst and Investor Day on
View HTML
Toggle Summary Anika to Participate in the 2019 Morgan Stanley Global Healthcare Conference on September 10, 2019
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that Joseph Darling , President and
View HTML
Toggle Summary Anika Announces Successful Completion of First Human Surgical Procedure with Injectable HA-Based Bone Repair Therapy
Company to Deploy Hybrid Commercial Strategy to Support U.S.Sales and Distribution BEDFORD, Mass. --(BUSINESS WIRE)--Aug. 13, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
View HTML
Toggle Summary Anika Reports Second Quarter 2019 Financial Results
Delivers Strong Bottom Line Performance with $0.67 Diluted EPS CINGAL Revenue Drives International Viscosupplement Revenue Growth of 28% Year-over-Year Announces Decision to Advance CINGAL Program Towards U.S. Regulatory Approval Raises Full Year 2019 Revenue and Adjusted EBITDA Guidance BEDFORD,
View HTML
Toggle Summary Anika to Exhibit its HA-Based Bone Repair Therapy at the 2019 American Orthopaedic Society for Sports Medicine Annual Meeting
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 11, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to exhibit its injectable,
View HTML